C

CytomX Therapeutics

CTMX

1.34000
USD
-0.04
(-2.90%)
Market Closed
Volume
64,760
EPS
0
Div Yield
0
P/E
7
Market Cap
85,148,185
Related Instruments
A
ALLO
-0.21500
(-7.29%)
2.73500 USD
B
BLUE
-0.06000
(-5.26%)
1.08000 USD
C
CRSP
-2.450
(-4.28%)
54.840 USD
E
EDIT
-0.28500
(-5.26%)
5.13500 USD
F
FATE
-0.46000
(-8.61%)
4.88000 USD
G
GLPG
0.270
(1.01%)
26.970 USD
S
SGMO
-0.09690
(-12.11%)
0.70340 USD
V
VCEL
-2.900
(-5.72%)
47.800 USD
News

Title: CytomX Therapeutics

Sector: Healthcare
Industry: Biotechnology
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.